Clinical trial
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
NCT00386061 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00386061 |
|---|---|
| Title | Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | rimonabant (SR141716) |
| Enrollment | 1,507 |
| Start date | Oct 1, 2001 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Oct 11, 2006 |
| Last update posted | Apr 20, 2009 |
| Countries | Belgium, Finland, France, Germany, Netherlands, Sweden, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: